IMRX — Immuneering Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1790340 ·
Last close
$5.27
Market Cap
$340.96M
52W High
$6.89
52W Low
$4.67
ADV30
1,134,360
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -15,334,539 | -13,460,895 | 214,809,790 | 47,321,566 | 8,291,619 |
| Dec 2025 | 0 | — | -13,751,943 | -11,580,010 | 231,985,010 | 128,645,025 | 13,501,042 |
| Sep 2025 | 0 | — | -15,380,300 | -14,964,875 | 241,056,266 | 227,563,077 | 13,079,834 |
| Jun 2025 | 0 | — | -14,757,477 | -14,433,881 | 40,056,468 | 26,355,498 | 11,120,431 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,344,595
Investing CF
$-88,738,247
Financing CF
$226,583,147
CapEx
$-142,226
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.38
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-280,320,084
Inventory
—
Receivables
—
ST Investments
$44,186,244
EBIT TTM
$-59,374,730
Pretax Income TTM
$-56,023,657
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,375,728 | -56,024,898 | 231,985,010 | 13,501,042 | — | -45,344,595 |
| Dec 2024 | 0 | -64,071,655 | -61,036,608 | 52,714,413 | 11,328,187 | — | -54,999,571 |
| Dec 2023 | 0 | -58,413,285 | -53,471,622 | 102,584,538 | 12,008,355 | — | -48,968,634 |
| Dec 2022 | 316,952 | -51,745,339 | -50,513,568 | 122,367,283 | 12,517,028 | — | -44,101,265 |
TTM Snapshot
Revenues TTM
$1,751,499
NetIncome TTM
$-53,234,615
OpCashFlow TTM
$0
Assets (Latest)
$52,714,413
Forward EPS
$-1.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DMAC | DiaMedica Therapeutics Inc. | $340.54M | $6.32 | — |
| ORGO | Organogenesis Holdings Inc. | $342.27M | $2.66 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $343.46M | $0.21 | — |
| SIGA | SIGA TECHNOLOGIES INC | $334.95M | $4.67 | — |
| IRD | Opus Genetics, Inc. | $332.91M | $4.09 | — |
News headlines (Yahoo Finance, 1h cache)
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
2026-05-21 21:00 · Yahoo
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-15 11:35 · Yahoo
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
2026-05-06 14:53 · Yahoo
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
2026-04-21 20:05 · Yahoo
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
2026-04-20 13:00 · Yahoo
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
2026-04-14 07:02 · Yahoo
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-06 20:05 · Yahoo
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
2026-03-17 20:35 · Yahoo
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
2026-03-09 15:15 · Yahoo
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-03-06 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.